Intra-coronary administration of soluble receptor for advanced glycation end-products attenuates cardiac remodeling with decreased myocardial transforming growth factor-β1 expression and fibrosis in minipigs with ischemia-reperfusion injury

• DOI: 10.3760/cma.j.issn.0366-6999.2010.05.017
• Publication Date: 2024-01-16T15:57:57Z
• Authors: Lin LU; Qi ZHANG; Yan XU; Zheng-bin ZHU; Liang GENG; Ling-jie WANG; Cao JIN; Qiu-jing CHEN; Ann Marie Schmidt; Wei-feng SHEN
• Keywords: Ventricular remodeling; Sirius Red; Myocardial fibrosis; Cardiac Fibrosis

Background The cardioprotective effects of soluble receptor for advanced glycation end-products (sRAGE) have not been evaluated in large animals and the underlying mechanisms are fully understood. This study aimed to evaluate intra-coronary administration sRAGE on left ventricular function myocardial remodeling a porcine model ischemia-reperfusion (I/R) injury. Methods Ten male minipigs with I/R injury were randomly allocated receive (sRAGE group, n=5) or saline (control n=5). Echocardiography was performed before 2 months after infarction. Myocardial expression transforming growth factor (TGF)-β1 determined by immunohistochemistry fibrosis Sirius red staining. Results As compared baseline values control animals, end-diastolic volume (from (19.5±5.1) (32.3±5.6) ml, P <0.05) end-systolic (8.3±3.2) (15.2±4.1) significantly increased, whereas ejection fraction decreased (61.6±13.3)% (50.2±11.9)%, <0.05). No obvious change these parameters observed group. TGF-β1 elevated infarct non-infarct regions as group (both <0.01). Fibrotic lesions consistently more prominent region myocardium ( Conclusion Intra-coronary attenuates RAGE-mediated through TGF-β1-dependent mechanism, suggesting clinical potential treating RAGE/ligand-associated cardiovascular diseases.